Epoetin alfa Other names: Erythropoietin

PubChem compound: 92043599

Therapeutic indications

Epoetin alfa is indicated for:

Anaemia associated with chronic renal failure (CRF)

Population group: only adults (18 years old or older)

Epoetin alfa is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (CRF):

in adults on haemodialysis and adult patients on peritoneal dialysis.
in adults with renal insufficiency not yet undergoing dialysis for the treatment of severe anaemia of renal origin accompanied by clinical symptoms in patients.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

25-75 IU/kg once every 2 days

25-75 IU/kg once every 2 days

Anaemia associated with chemotherapy

Population group: only adults (18 years old or older)

Epoetin alfa is indicated in adults receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient’s general status (e.g. cardiovascular status, pre-existing anaemia at the start of chemotherapy) for the treatment of anaemia and reduction of transfusion requirements.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

450 IU/kg once every week

150 IU/kg once every 2 days

Autologous blood predonation programme

Population group: only adults (18 years old or older)

Epoetin alfa is indicated in adults in a predonation programme to increase the yield of autologous blood. Treatment should only be given to patients with moderate anaemia (haemoglobin [Hb] concentration range between 10 to 13 g/dL [6.2 to 8.1 mmol/L], no iron deficiency), if blood saving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males).

For this indication, competent medicine agencies globally authorize below treatments (click for details):

600 IU/kg once every 2 days

Anaemia with risk of primary myelodysplastic syndromes (MDS) who have low serum erythropoietin

Population group: only adults (18 years old or older)

Epoetin alfa is indicated for the treatment of symptomatic anaemia (haemoglobin concentration of ≤10 g/dL) in adults with low- or intermediate-1-risk primary myelodysplastic syndromes (MDS) who have low serum erythropoietin (<200 mU/mL).

For this indication, competent medicine agencies globally authorize below treatments (click for details):

450 IU/kg once every week

Anaemia associated with chronic renal failure (CRF)

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old)

Epoetin alfa is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (CRF) in children aged 1 to 18 years on haemodialysis.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

25-75 IU/kg once every 2 days

Contraindications

Epoetin alfa is contraindicated in the following cases:

Uncontrolled hypertension

Hypertensive crisis

Major orthopaedic surgery, coronary, peripheral arterial, cerebral vascular disease, cerebral vascular accident

at least one of

Operation on musculoskeletal system
Coronary arteriosclerosis
Peripheral arterial vascular disease
Cerebrovascular disease
Disorder of carotid artery
CVA - Cerebrovascular accident
Myocardial infarction

Pure red cell aplasia (PRCA)

Antibody mediated acquired pure red cell aplasia caused by erythropoiesis stimulating agent

< Previous: Overview

Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈